Duchenne Muscular Dystrophy - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 237 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Duchenne Muscular Dystrophy - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Duchenne Muscular Dystrophy - Pipeline Review, H1 2015', provides an overview of the Duchenne Muscular Dystrophy's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Duchenne Muscular Dystrophy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Duchenne Muscular Dystrophy and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Duchenne Muscular Dystrophy
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Duchenne Muscular Dystrophy and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Duchenne Muscular Dystrophy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Duchenne Muscular Dystrophy pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Duchenne Muscular Dystrophy
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Duchenne Muscular Dystrophy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Duchenne Muscular Dystrophy Overview 9
Therapeutics Development 10
Pipeline Products for Duchenne Muscular Dystrophy - Overview 10
Pipeline Products for Duchenne Muscular Dystrophy - Comparative Analysis 11
Duchenne Muscular Dystrophy - Therapeutics under Development by Companies 12
Duchenne Muscular Dystrophy - Therapeutics under Investigation by Universities/Institutes 16
Duchenne Muscular Dystrophy - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Duchenne Muscular Dystrophy - Products under Development by Companies 20
Duchenne Muscular Dystrophy - Products under Investigation by Universities/Institutes 25
Duchenne Muscular Dystrophy - Companies Involved in Therapeutics Development 26
Acceleron Pharma, Inc. 26
Asklepios BioPharmaceutical, Inc. 27
Bristol-Myers Squibb Company 28
Catabasis Pharmaceuticals, Inc. 29
Daiichi Sankyo Company, Limited 30
Eli Lilly and Company 31
EryDel SPA 32
Fate Therapeutics, Inc. 33
Galapagos NV 34
Genethon 35
Idera Pharmaceuticals, Inc. 36
Italfarmaco S.p.A. 37
Marathon Pharmaceuticals, LLC 38
Marina Biotech, Inc. 39
miRagen Therapeutics, Inc. 40
NicOx S.A. 41
Nippon Shinyaku Co., Ltd. 42
nLife Therapeutics, S.L. 43
Nobelpharma Co., Ltd. 44
Pfizer Inc. 45
Prosensa Therapeutics B.V. 46
Prothelia, Inc. 47
PTC Therapeutics, Inc. 48
Reata Pharmaceuticals, Inc. 49
Retrophin Inc. 50
ReveraGen BioPharma, Inc. 51
Sanofi 52
Santhera Pharmaceuticals Holding AG 53
Sarepta Therapeutics, Inc. 54
Shenzhen Beike Biotechnology Co., Ltd. 55
Shire Plc 56
Summit Corporation plc 57
Taiho Pharmaceutical Co., Ltd. 58
Zambon Company S.p.A. 59
Duchenne Muscular Dystrophy - Therapeutics Assessment 60
Assessment by Monotherapy Products 60
Assessment by Combination Products 61
Assessment by Target 62
Assessment by Mechanism of Action 64
Assessment by Route of Administration 66
Assessment by Molecule Type 68
Drug Profiles 70
AAV1-FS-344 - Drug Profile 70
ACE-083 - Drug Profile 71
Antisense Oligonucleotide for Duchenne Muscular Dystrophy - Drug Profile 72
Antisense Oligonucleotide to Activate Dystrophin for Duchene Muscular Dystrophy - Drug Profile 73
Antisense Oligonucleotide to Inhibit Myostatin for DMD and Becker MD - Drug Profile 74
Aptamer to Activate Calcineurin A for Genetic Disorders and Musculoskeletal Disorders - Drug Profile 75
arbekacin - Drug Profile 76
ARM-210 - Drug Profile 77
AT-300 - Drug Profile 78
ataluren - Drug Profile 80
Biostrophin - Drug Profile 83
BMS-986089 - Drug Profile 84
CAT-1004 - Drug Profile 85
CAT-1040 - Drug Profile 87
CAT-1041 - Drug Profile 88
deflazacort - Drug Profile 89
dexamethasone sodium phosphate - Drug Profile 90
drisapersen - Drug Profile 92
Drugs for Duchenne Muscular Dystrophy - Drug Profile 94
DT-200 - Drug Profile 95
eteplirsen - Drug Profile 97
Gene Therapy for Duchenne Muscular Dystrophy - Drug Profile 100
Gene Therapy to Activate Dysferlin for Duchenne and Limb Girdle Muscular Dystrophies - Drug Profile 101
Gene Therapy to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile 102
givinostat - Drug Profile 103
halofuginone hydrobromide - Drug Profile 105
idebenone - Drug Profile 108
IMO-8400 - Drug Profile 110
MG-53 - Drug Profile 112
MGN-8107 - Drug Profile 114
naproxcinod - Drug Profile 115
NBD Peptide - Drug Profile 117
NS-065 - Drug Profile 119
NU-21101 + NU-21502 - Drug Profile 120
Oligonucleotides for Ischemic Heart Disease and Duchenne Muscular Dystrophy - Drug Profile 121
OSX-200 - Drug Profile 122
Peptides for Duchenne Muscular Dystrophy and Cardiac Disease - Drug Profile 123
PF-06252616 - Drug Profile 124
poloxamer - Drug Profile 125
PRO-044 - Drug Profile 127
PRO-045 - Drug Profile 129
PRO-052 - Drug Profile 131
PRO-053 - Drug Profile 133
PRO-055 - Drug Profile 135
PROSPECT - Drug Profile 136
PRT-01 - Drug Profile 137
PRT-20 - Drug Profile 138
PRT-300 - Drug Profile 139
PRT-400 - Drug Profile 140
PRT-500 - Drug Profile 141
RE-001 - Drug Profile 142
Recombinant Protein for Muscular Dystrophy - Drug Profile 143
Recombinant Proteins for Duchenne Muscular Dystrophy - Drug Profile 144
RNAi Oligonucleotides for Duchenne Muscular Dystrophy - Drug Profile 145
RTC-13 - Drug Profile 146
SHP-619 - Drug Profile 148
Small Molecule for Duchenne Muscular Dystrophy - Drug Profile 149
Small Molecule for Muscular Dystrophy and Other Muscle Disorders - Drug Profile 150
Small Molecule to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile 152
Small Molecule to Activate Utrophin for Duchenne Muscular Dystrophy - Drug Profile 153
Small Molecules to Activate Nrf2 for Duchenne Muscular Dystrophy - Drug Profile 154
Small Molecules to Activate Utrophin for Duchenne Muscular Dystrophy - Drug Profile 155
Small Molecules to Target Utrophin for Duchenne Muscular Dystrophy - Drug Profile 156
SMTC-1100 - Drug Profile 157
SRP-4008 - Drug Profile 159
SRP-4044 - Drug Profile 160
SRP-4045 - Drug Profile 161
SRP-4050 - Drug Profile 162
SRP-4052 - Drug Profile 163
SRP-4053 - Drug Profile 164
SRP-4055 - Drug Profile 165
Stem Cell Therapy for Duchenne Muscular Dystrophy - Drug Profile 166
Stem Cell Therapy to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile 167
tadalafil - Drug Profile 169
TAS-205 - Drug Profile 171
TVN-102 - Drug Profile 172
TXA-127 - Drug Profile 173
VBP-15 - Drug Profile 175
ZP-049 - Drug Profile 177
Duchenne Muscular Dystrophy - Recent Pipeline Updates 178
Duchenne Muscular Dystrophy - Dormant Projects 220
Duchenne Muscular Dystrophy - Discontinued Products 222
Duchenne Muscular Dystrophy - Product Development Milestones 223
Featured News & Press Releases 223
Appendix 230
Methodology 230
Coverage 230
Secondary Research 230
Primary Research 230
Expert Panel Validation 230
Contact Us 230
Disclaimer 231

List of Tables
Number of Products under Development for Duchenne Muscular Dystrophy, H1 2015 16
Number of Products under Development for Duchenne Muscular Dystrophy - Comparative Analysis, H1 2015 17
Number of Products under Development by Companies, H1 2015 19
Number of Products under Development by Companies, H1 2015 (Contd..1) 20
Number of Products under Development by Companies, H1 2015 (Contd..2) 21
Number of Products under Investigation by Universities/Institutes, H1 2015 22
Comparative Analysis by Late Stage Development, H1 2015 23
Comparative Analysis by Clinical Stage Development, H1 2015 24
Comparative Analysis by Early Stage Development, H1 2015 25
Products under Development by Companies, H1 2015 26
Products under Development by Companies, H1 2015 (Contd..1) 27
Products under Development by Companies, H1 2015 (Contd..2) 28
Products under Development by Companies, H1 2015 (Contd..3) 29
Products under Development by Companies, H1 2015 (Contd..4) 30
Products under Investigation by Universities/Institutes, H1 2015 31
Duchenne Muscular Dystrophy - Pipeline by Acceleron Pharma, Inc., H1 2015 32
Duchenne Muscular Dystrophy - Pipeline by Asklepios BioPharmaceutical, Inc., H1 2015 33
Duchenne Muscular Dystrophy - Pipeline by Bristol-Myers Squibb Company, H1 2015 34
Duchenne Muscular Dystrophy - Pipeline by Catabasis Pharmaceuticals, Inc., H1 2015 35
Duchenne Muscular Dystrophy - Pipeline by Daiichi Sankyo Company, Limited, H1 2015 36
Duchenne Muscular Dystrophy - Pipeline by Eli Lilly and Company, H1 2015 37
Duchenne Muscular Dystrophy - Pipeline by EryDel SPA, H1 2015 38
Duchenne Muscular Dystrophy - Pipeline by Fate Therapeutics, Inc., H1 2015 39
Duchenne Muscular Dystrophy - Pipeline by Galapagos NV, H1 2015 40
Duchenne Muscular Dystrophy - Pipeline by Genethon, H1 2015 41
Duchenne Muscular Dystrophy - Pipeline by Idera Pharmaceuticals, Inc., H1 2015 42
Duchenne Muscular Dystrophy - Pipeline by Italfarmaco S.p.A., H1 2015 43
Duchenne Muscular Dystrophy - Pipeline by Marathon Pharmaceuticals, LLC, H1 2015 44
Duchenne Muscular Dystrophy - Pipeline by Marina Biotech, Inc., H1 2015 45
Duchenne Muscular Dystrophy - Pipeline by miRagen Therapeutics, Inc., H1 2015 46
Duchenne Muscular Dystrophy - Pipeline by NicOx S.A., H1 2015 47
Duchenne Muscular Dystrophy - Pipeline by Nippon Shinyaku Co., Ltd., H1 2015 48
Duchenne Muscular Dystrophy - Pipeline by nLife Therapeutics, S.L., H1 2015 49
Duchenne Muscular Dystrophy - Pipeline by Nobelpharma Co., Ltd., H1 2015 50
Duchenne Muscular Dystrophy - Pipeline by Pfizer Inc., H1 2015 51
Duchenne Muscular Dystrophy - Pipeline by Prosensa Therapeutics B.V., H1 2015 52
Duchenne Muscular Dystrophy - Pipeline by Prothelia, Inc., H1 2015 53
Duchenne Muscular Dystrophy - Pipeline by PTC Therapeutics, Inc., H1 2015 54
Duchenne Muscular Dystrophy - Pipeline by Reata Pharmaceuticals, Inc., H1 2015 55
Duchenne Muscular Dystrophy - Pipeline by Retrophin Inc., H1 2015 56
Duchenne Muscular Dystrophy - Pipeline by ReveraGen BioPharma, Inc., H1 2015 57
Duchenne Muscular Dystrophy - Pipeline by Sanofi, H1 2015 58
Duchenne Muscular Dystrophy - Pipeline by Santhera Pharmaceuticals Holding AG, H1 2015 59
Duchenne Muscular Dystrophy - Pipeline by Sarepta Therapeutics, Inc., H1 2015 60
Duchenne Muscular Dystrophy - Pipeline by Shenzhen Beike Biotechnology Co., Ltd., H1 2015 61
Duchenne Muscular Dystrophy - Pipeline by Shire Plc, H1 2015 62
Duchenne Muscular Dystrophy - Pipeline by Summit Corporation plc, H1 2015 63
Duchenne Muscular Dystrophy - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2015 64
Duchenne Muscular Dystrophy - Pipeline by Zambon Company S.p.A., H1 2015 65
Assessment by Monotherapy Products, H1 2015 66
Assessment by Combination Products, H1 2015 67
Number of Products by Stage and Target, H1 2015 69
Number of Products by Stage and Mechanism of Action, H1 2015 71
Number of Products by Stage and Route of Administration, H1 2015 73
Number of Products by Stage and Molecule Type, H1 2015 75
Duchenne Muscular Dystrophy Therapeutics - Recent Pipeline Updates, H1 2015 184
Duchenne Muscular Dystrophy - Dormant Projects, H1 2015 226
Duchenne Muscular Dystrophy - Dormant Projects (Contd..1), H1 2015 227
Duchenne Muscular Dystrophy - Discontinued Products, H1 2015 228